# Aprea Therapeutics, Inc. (APRE) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_07205fd65b6c78dda94e · retrieved 2026-08-11T15:54:05.545Z

## Overview
Aprea Therapeutics, Inc. is a pharmaceutical company engaged in the development of therapeutic treatments.

On July 23, 2026, Aprea Therapeutics, Inc. received notification from Nasdaq that while the company has not yet regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2), it has been granted an additional 180 calendar day period, or until January 19, 2027 (the "Second Compliance Period"), to regain compliance. The company was initially provided 180 calendar days from January 23, 2026 (until July 22, 2026) to regain compliance. If the closing bid price of the common stock reaches at least $1.00 per share for a minimum of 10 consecutive business days during the Second Compliance Period, Nasdaq will provide written confirmation of compliance. If compliance cannot be demonstrated by January 19, 2027, Nasdaq will provide written notification that the common stock will be delisted from Nasdaq, at which time the company may appeal the determination to a hearings panel.

## Terms
- Counterparty: The Nasdaq Stock Market LLC · Price/share: $1

## Key dates
- Announced 2026-07-23 · Expiry 2027-01-19

## Timeline
- 2026-07-23 · 8-K (0001104659-26-086254): 8-K - Aprea Therapeutics, Inc. — *Aprea Therapeutics, Inc. is a pharmaceutical company engaged in the development of therapeutic treatments.* On July 23, 2026, Aprea Therapeutics, Inc. received notification from Nasdaq that while the company has not yet regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2), it has been granted an additional 180 calendar day period, or until January 19, 2027 (the "Second Compliance Period"), to regain compliance. The company was initially provided 180 calendar days from January 23, 2026 (until July 22, 2026) to regain compliance. If the closing bid price of the common stock reaches at least $1.00 per share for a minimum of 10 consecutive business days during the Second Compliance Period, Nasdaq will provide written confirmation of compliance. If compliance cannot be demonstrated by January 19, 2027, Nasdaq will provide written notification that the common stock will be delisted from Nasdaq, at which time the company may appeal the determination to a hearings panel.
  https://www.sec.gov/Archives/edgar/data/1781983/0001104659-26-086254.txt

## Citations
- 0001104659-26-086254 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926086254